SIRTLab Corporation

SIRTLab Corporation is a developer of therapies for liver diseases and age-related conditions. SIRTLab focuses on the pharmacological modulation of SIRT6, a key orchestrator of multiple processes involving triglyceride and lipid metabolism, glucose, inflammation, chromosome maintenance, and cellular homeostasis. The company anticipates that initial research will concentrate on moderate to severe nonalcoholic steatohepatitis (NASH), with many other applications, including various aspects of other chronic liver diseases, metabolic syndrome, and age-related conditions.